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ABSTRACT
Background: Since September 2015, the initiation of antiviral therapy (AVT) for patients with 
chronic hepatitis B (CHB)-related cirrhosis has been reimbursed according to the revised 
Korean Association for the Study of Liver (KASL) guideline, if the patient had hepatitis B 
virus DNA level ≥ 2,000 IU/L, regardless of aminotransferase or alanine aminotransferase 
levels. This study investigated whether the KASL guideline implementation reduced the risk 
of CHB-related hepatocellular carcinoma (HCC) in patients with cirrhosis in South Korea.
Methods: A total of 429 patients with CHB-related cirrhosis who initiated AVT between 2014 
and 2016 were recruited. The risk of HCC development was compared between patients who 
initiated AVT before and after September 2015 (pre-guideline [n = 196, 45.7%] vs. post-
guideline implementation [n = 233, 54.3%]).
Results: Univariate analysis showed that AVT initiation before guideline implementation, 
older age, male gender, and diabetes significantly predicted increased risk of HCC 
development (all P < 0.05). Subsequent multivariate analysis showed that AVT initiation 
before guideline implementation (HR = 1.941), older age (HR = 5.762), male gender 
(HR = 2.555), and diabetes (HR = 1.568) independently predicted increased risk of HCC 
development (all P < 0.05). Additionally, multivariate analysis showed that AVT initiation 
before guideline implementation (HR = 2.309), male gender (HR = 3.058), and lower platelet 
count (HR = 0.989) independently predicted mortality (P < 0.05). The cumulative incidences 
of HCC and mortality were significantly higher in patients who initiated AVT before guideline 
implementation than in those who initiated AVT after guideline implementation (all P < 0.05, 
log-rank test).
Conclusion: The prognosis of patients with CHB-related cirrhosis who initiated AVT 
improved after guideline implementation according to the revised KASL guideline.
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INTRODUCTION
Hepatitis B virus (HBV) causes significant human morbidity and mortality worldwide with 
>240 million people infected.1,2 Chronic hepatitis B (CHB) is correlated with higher risk of 
compensated cirrhosis and hepatocellular carcinoma (HCC), with over 20% of patients with 
CHB progressing to HCC within 10 years.3,4 Research has shown that the risk of progression 
to end-stage complications is associated with HBV replication, as assessed with serum HBV 
DNA levels.5 Thus, suppression of HBV replication with antiviral therapy (AVT) is the primary 
treatment strategy to prevent poor patient outcomes.2,6 Oral AVT may prevent disease 
progression and development of HCC.7 Newer oral AVT agents such as entecavir (ETV) and 
tenofovir have a high genetic barrier to resistance, making them good candidates for first-line 
CHB therapy.8,9 However, the optimal timing for initiating AVT, especially for patients with 
cirrhosis, is still under debate.10
In 2007, the Korean Association for the Study of the Liver (KASL) published its guideline 
proposing new initiation criteria for AVT in patients with CHB-related cirrhosis, when 
both elevated serum HBV DNA (HBV DNA ≥ 2,000 IU/mL) and elevated aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) (AST or ALT ≥ 40 IU/L) were 
identified. Implementation of National Health Insurance Service (NHIS) reimbursement 
for AVT in these patients started from October 1, 2010. However, it has been argued that 
liver enzyme levels are not indicative of advanced CHB progression and should not be 
used as a criterion to determine the initiation of AVT.11 In addition, studies have shown 
that patients with significant hepatic fibrosis frequently have almost normal AST and ALT 
levels.12,13 Accordingly, this concept has been reflected in various international guidelines 
for AVT treatment for patients with compensated CHB-related cirrhosis.14-16 Therefore, the 
2012 KASL clinical practice guidelines have also reflected this concept and recommended 
initiating AVT for patients with compensated CHB-related cirrhosis with elevated HBV 
DNA (HBV DNA ≥ 2,000 IU/mL), regardless of AST or ALT levels.12 Medical insurance 
reimbursement for AVT in those patients was implemented on September 1, 2015. However, 
no research has shown improved prognosis of earlier AVT initiation for patients with 
compensated CHB-related cirrhosis.
Therefore, we investigated whether the major change in KASL guidelines, implemented on 
September 1, 2015, reduced the risk of CHB-related HCC in patients with cirrhosis in South Korea.
METHODS
Treatment-naïve patients with compensated CHB-related cirrhosis who initiated AVT with 0.5 
mg/day ETV or 300 mg/day tenofovir disoproxil fumarate (TDF) between July 1, 2014 and August 
31, 2015 according to the previous KASL guideline implementation and between September 1, 
2015 and October 31, 2016 according to the current KASL guideline implementation from two 
academic teaching hospitals (Yonsei University Health System [YUHS] and Kyungpook National 
University Hospital [KNUH]) were considered eligible for study.
Because the current AVT guideline was implemented through the NHIS reimbursement 
program on September 1, 2015, the enrollment periods were matched with 14 months before 
September 1, 2015 as pre-guideline implementation cohort and 14 months after September 1, 
2015 as the post-guideline implementation cohort, to ensure a sufficient follow-up period for 
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the post-guideline implementation cohort. Thus, the enrollment period for the pre-guideline 
implementation and post-guideline implementation cohort was from July 1, 2014 to August 
31, 2015 and from September 1, 2015 to October 31, 2016, respectively. Furthermore, to 
match the follow-up duration between cohorts, the last follow-up date of the pre-guideline 
implementation cohort and of the post-guideline implementation cohort was April 30, 
2018 and June 30, 2019, respectively, resulting in a follow-up duration ranging from 32 to 46 
months (Fig. 1). The median follow-up was 36.3 months (interquartile range, IQR 6.9–36.9) 
and was not significantly different between cohorts (P = 0.882).
Exclusion criteria included 1) previous AVT; 2) previous HCC; 3) decompensated cirrhosis; 
4) previous liver transplantation; 5) co-infection with hepatitis C virus or human 
immunodeficiency virus (HIV); 6) significant combined medical illness; 7) concomitant drug-
induced, autoimmune, or alcoholic liver diseases; 8) pregnant or breastfeeding women; and 
9) insufficient clinical information based on prescription records and chart review (Fig. 2). 
Owing to our homogenous study population, data on race/ethnicity were not collected.
In the Republic of Korea (ROK), the reimbursement criteria for ETV or TDF were identical 
during the study period. If histological information was not available, compensated cirrhosis 
was clinically defined as follows: 1) platelet count < 150,000/μL and ultrasonographic 
findings suggestive of compensated cirrhosis, including a blunted, nodular liver surface 
accompanied with splenomegaly (> 12 cm) or 2) esophageal or gastric varices.
Ethics statement
Our study methodology was in accordance with the ethics guidelines of the 1975 Declaration 
of Helsinki and approved by the Institutional Review Board (IRB) of the two institutes (IRB 
No. 4-2019-0713). Informed consent was waived due to the retrospective nature of the study.
Clinical follow-up and outcomes
During the follow-up period, all patients had routine blood chemistry testing, HBV DNA 
level testing, and viral marker testing every 3–6 months. Patients were also screened 
for HCC according to alpha-fetoprotein level and ultrasonography every six months. If 
ultrasonographic assessment for HCC identification was not satisfactory, dynamic imaging 
studies were performed depending on physicians' decision.
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Pre-AVT guideline implementation
enroll [14 months]
(July 1st, 2014–August 31st, 2015)





(September 1st, 2015–October 31st, 2016)
Reimbursement
Regardless of AST/ALT level
Post-AVT guideline implementation follow-up
[32–46 months]
(–June 30th, 2019)
2014 2015 2016 2017 2018 2019
Fig. 1. Diagram of cohort enrollment and follow-up period. Patients were enrolled based on AVT start date. The pre- and post-guideline implementation cohort was 
separated in September 1st, 2015, which is the start date for National Health Insurance Service medical insurance reimbursement for cirrhotic chronic hepatitis 
B patients with HBV DNA > 2,000 IU/mL, regardless of AST/ALT levels. The enrollment period for the pre-guideline implementation cohort was from July 1st, 2014 
to August 31st, 2015 and the post guideline implementation cohort was from September 1st, 2015 to October 31st, 2016 (both 14 months). Follow up periods were 
matched for both cohorts to a maximum of 45 months, until April 30th, 2018 and June 30th, 2019 for the previous and current AVT guideline cohort, respectively. 
AVT = antiviral therapy, AST = aspartate aminotransferase, ALT = alanine aminotransferase, HBV = Hepatitis B virus.
The primary clinical outcome was HCC development, which was diagnosed based on 
histology or dynamic computed tomography and/or magnetic resonance imaging (nodule 
size > 1 cm) with increased arterial enhancement followed by decreased enhancement 
compared with the liver (washout) in the portal/delayed phase.17 The second clinical outcome 
was mortality. The index date was the date of first AVT prescription, and the follow-up period 
was estimated from the index date until HCC diagnosis, death, or final follow-up.
To increase the stability of our comparison, follow-up cut-off dates were designed to ensure 
similar follow-up periods for both cohorts. Since the enrollment start dates for the cohorts were 
independent, follow up dates were matched to better compare the outcome rates of the two 
cohorts. Furthermore, unequal follow-up periods could lead to additional bias in our study.18
NHIS data analysis
The NHIS database of South Korea is a nationwide health insurance database organized 
by the government of Korea that records all forms of health-care utilization, including 
hospitalization, drug prescriptions, and outpatient care for the entire South Korean 
population. All information regarding health-care utilization is registered by health facilities 
in a comprehensive database operated by the Health Insurance and Review Agency (HIRA). 
The HIRA database is a collection of information on patients such as outpatient and inpatient 
status, drug prescriptions, procedures, demographics, and diagnoses as organized by the 
International Classification of Diseases 10th revision (ICD-10) codes.
We selected patients who both had a claims data diagnosis of liver cirrhosis (ICD-10: 
K74 or B18) and received prescription for either ETV or tenofovir between July 2014 and 
October 2016 while not being on medication for the year prior to prescription. Patients 
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Between July 2014 and October 2016, 218 patients
with CHB-related cirrhosis treated with entecavir
or tenofovir were considered eligible (YUHS)
History of decompensation
History of liver transplantation
Co-infection with hepatitis C virus or HIV
Significant combined medical illness
Concommitant drug-induced, autoimmune, or alcoholic liver diseases
Pregnant or breastfeeding women
Insufficient clinical data
History of antiviral therapy
History of hepatocellular carcinoma
187 cirrhotic patients with treatment-naïve CHB
168 patients were selected
429 patients were recruited for the statistical analysis
Between July 2014 and October 2016, 323 patients
with CHB-related cirrhosis treated with entecavir
or tenofovir were considered eligible (KNUH)
286 cirrhotic patients with treatment-naïve CHB
261 patients were selected
Fig. 2. Flow of study population selection process. A total of 218 patients from YUHS and 323 patients from KNUH with CHB treated with entecavir or tenofovir 
between July 2014 and October 2016 were considered eligible for participation. After exclusion of 50 and 37 patients from YUHS and KNUH, respectively, 
according to our exclusion criteria, 168 patients from YUHS and 261 patients from KNUH were ultimately included for statistical analysis. 
YUHS = Yonsei University Health System, KNUH = Kyungpook National University Hospital, CHB = chronic hepatitis B, HIV = human immunodeficiency virus.
with a diagnosis for cancer of any type, previous AVT, co-infection with hepatitis C virus or 
HIV, significant combined medical illness, concomitant drug-induced, autoimmune liver 
diseases in the two years prior to entercavir or tenoforvir prescription, or with a previous liver 
transplant, were excluded. Outcome was defined as incidence of HCC (ICD-10: C22 and rare 
incurable disease code). In order to match the follow-up duration between the pre-guideline 
implementation cohort and the post-guideline implementation cohort, the final follow-up 
dates were October 31, 2017 and December 31, 2018 respectively, resulting in a follow-up 
duration of 26 to 40 months.
Statistical analysis
Continuous variables are expressed as median with IQR, whereas categorical variables are 
expressed as numbers (%). Differences between baseline characteristics were examined 
using the χ2 test for categorical values and the Student's t-test for continuous variables. 
Cumulative risk of HCC and mortality was calculated using the Kaplan-Meier method and 
compared using the log-rank test. Independent risk factors for HCC and mortality were 
estimated using multivariate Cox proportional hazard regression analysis. Because all 
patients had compensated liver function at the time of AVT initiation, the variables of Child-
Turcotte-Pugh class were not included in the multivariate analysis. Statistical analyses were 
performed using SPSS software 25.0 for Windows (SPSS Inc., Chicago, IL, USA), and two-
tailed P < 0.05 was considered statistically significant.
For analyzing NHIS data, subdistribution hazard ratios were estimated using a Cox 
subdistribution regression model while accounting for the competing risks of death and liver 
transplantation. To control for confounding, we adjusted for variables such as age, gender, 
and history of diabetes mellitus. Analyses were performed using the SAS Enterprise Guide 
(SAS Institute, Inc., Cary, NC, USA), and P < 0.05 was considered statistically significant.
Propensity score matching (PSM) was used with a 1:1 ratio and adjusted for age, gender, HBV 
DNA, and hepatitis B virus e antigen (HBeAg). A caliper of 0.2 standard deviations of the 




After excluding 50 and 62 patients from the YUHS and KNUH cohorts, respectively, based 
on our exclusion criteria, 168 patients from YUHS and 261 from KNUH with compensated 
CHB-related cirrhosis (247 men and 182 women) were included in the final statistical analysis 
(Fig. 1).
Baseline characteristics of the entire study population are shown in Table 1. Median age of the 
study population was 58.5 years. Diabetes was identified in 85 (19.8%) patients. The median 
ALT level was 43 (IQR, 32–67) and HBV DNA was 5.5 log IU/mL (IQR, 3.6–6.6). HBeAg was 
positive in 179 (41.7%) patients. ETV was initiated in 139 (32.4%) patients, whereas TDF was 
initiated in 290 (67.6%). Among patients who started AVT after September 2015, 123 patients 
(52.8%) had normal ALT levels and 114 patients (48.9%) had normal AST levels. Most 
baseline characteristics were similar between the two institutes (data not shown).
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Comparison of baseline characteristics according to AVT guideline 
implementation at treatment initiation
Although most characteristics were statistically similar, patients with AVT initiation before 
the guideline implementation (n = 196, 45.7%) had significantly higher AST level (median 52 
vs. 40 IU/L), ALT level (median 46 vs. 37 IU/L), higher HBV DNA level (median 5.7 vs. 5.1 log 
IU/mL), and higher proportion of TDF use (85.2% vs. 52.8%) than those with AVT initiation 
after the guideline implementation (n = 233, 54.3%) (all P < 0.05) (Table 1).
Comparison between patients who developed HCC and those who did not
Patients who developed HCC (n = 48, 11.2%) had a significantly higher age, higher percentage 
of male gender, lower serum albumin levels, and higher proportion of AVT initiation before 
the guideline implementation (all P < 0.05) than those who did not develop HCC (n = 381, 
88.8%) (data not shown).
Independent risk factors for HCC development
Univariate analysis showed that age, male gender, and pre-guideline implementation were 
significant risk factors for HCC development (all P < 0.05). On the subsequent multivariate 
analysis, together with age greater than 50 years old, higher proportion of male gender, and 
diabetes, AVT initiation before the guideline implementation was independently associated 
with a higher risk of HCC development (hazard ratio [HR], 1.941; 95% confidence interval 
[CI], 1.087–3.466; P = 0.025) (Table 2).
The cumulative incidence rate of HCC in patients with AVT initiation before the guideline 
implementation was significantly higher than that of patients with AVT initiation after the 
guideline (P = 0.041, log-rank test) (Fig. 3). The cumulative incidence of HCC for 1, 2, 3 years 
were 4.1%, 9.3%, and 15.3% for the pre-guideline implementation cohort and 2.6%, 5.4% 
and 7.9% for the post-guideline implementation cohort, respectively.
Comparison between patients with or without mortality and liver transplant
Patients with mortality (n = 25, 5.8%) had significantly lower serum albumin levels and lower 
platelet count (all P < 0.05) than those who survived (n = 404, 94.2%). In addition, patients with 
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Table 1. Baseline characteristics (n = 429)
Variables All Pre-guideline implementation  
(n = 196, 45.7%)
Post-guideline implementation  
(n = 233, 54.3%)
P value
Demographic data
Age, yr 58.5 (52.5–64.4) 58.9 (53.7–64.2) 58.0 (52.2–65.1) 0.732
Male gender 247 (57.6) 111 (56.6) 136 (58.4) 0.717
Body mass index, kg/m2 23.5 (21.5–25.5) 23.6 (21.5–25.3) 23.1 (21.5–25.6) 0.801
Diabetes 85 (19.8) 42 (21.4) 43 (18.5) 0.441
Laboratory data
Total bilirubin, mg/dL 0.9 (0.6–1.4) 0.9 (0.6–1.4) 0.9 (0.6–1.3) 0.885
Serum albumin, g/dL 4.0 (3.6–4.3) 4.0 (3.5–4.3) 4.0 (3.6–4.3) 0.152
Alanine aminotransferase, IU/L 43 (32–67) 46 (40–73) 37 (24–63) 0.026
Aspartate aminotransferase, IU/L 44 (38–68) 52 (40–76) 40 (28–59) 0.009
Platelet count, 109/L 108 (83–138) 106 (85–133) 111 (83–142) 0.299
Prothrombin time, INR 1.17 (1.07–1.30) 1.18 (1.07–1.29) 1.17 (1.07–1.30) 0.491
Alpha-fetoprotein, ng/mL 5.2 (3.0–11.0) 6.0 (3.2–12.2) 4.9 (2.8–9.5) 0.756
HBeAg positivity 179 (41.7) 88 (46.1) 91 (42.3) 0.448
HBV DNA, log IU/mL 5.5 (3.6–6.6) 5.7 (4.2–6.7) 5.1 (3.4–6.6) 0.017
Entecavir/tenofovir 139 (32.4)/290 (67.6) 29 (14.8)/167 (85.2) 110 (47.2)/123 (52.8) < 0.001
Variables are expressed as median (interquartile range) or number (%).
INR = international normalized ratio, HBeAg = hepatitis B e antigen, HBV = Hepatitis B virus.
liver transplant (n = 5, 1.2%) had significantly lower serum albumin levels and longer prothrombin 
time, INR (all P < 0.05) than those without liver transplant (n = 424, 98.8%) (data not shown).
Independent risk factors for mortality or liver transplant
Univariate analysis indicated male gender, platelet count, prothrombin time and pre-guideline 
implementation as significant risk factors for mortality or liver transplant (all P < 0.05). On 
the subsequent multivariate analysis, together with higher percentage of male gender and 
platelet count, pre-guideline implementation was independently associated with higher risk of 
mortality or liver transplant (HR, 2.400; 95% CI, 1.030–5.591; P = 0.043) (Table 3).
The cumulative incidence rate of mortality or transplantation in patients with AVT initiation 
before the guideline implementation was significantly higher than that of patients with 
AVT initiation after the guideline implementation (P = 0.022, log-rank test) (Fig. 3). The 
cumulative incidence of mortality or liver transplant for 1, 2, 3 years were 2.6%, 6.9%, and 
9.7% for the pre-guideline implementation cohort and 0.9%, 1.3% and 4.8% for the post-
guideline implementation cohort, respectively.
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Table 2. Cox regression analysis to identify independent risk factors for HCC
Variables Univariate Multivariate
P value HR 95% CI P value
Age, yr 0.023
Age > 50 yr 0.027 5.762 1.391–23.874 0.016
Male (vs. female) 0.010 2.555 1.317–4.954 0.006
Body mass index, kg/m2 0.523
Diabetes 0.024 1.568 0.846–2.909 0.153
Alanine aminotransferase, IU/L 0.365
Alanine aminotransferase > 40 IU/L 0.556
Aspartate aminotransferase, IU/L 0.908
Platelet count, 109/L 0.947
Alpha-fetoprotein, ng/mL 0.208
HBeAg positivity 0.728
HBV DNA, log IU/mL 0.573
Entecavir (vs. tenofovir) 0.396
Pre-guideline implementation (vs. post-guideline implementation) 0.039 1.941 1.087–3.466 0.025
HCC = hepatocellular carcinoma, HR = hazard ratio, CI = confidence interval, HBeAg = hepatitis B e antigen, HBV 
= Hepatitis B virus.
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Fig. 3. The cumulative incidence rates of HCC (A) and mortality or transplantation (B) according to antiviral therapy guideline implementation. The cumulative 
incidence risk of HCC and mortality or transplantation of patients in the pre-guideline implementation cohort was significantly higher than that of patients in the 
post-guideline implementation cohort (P = 0.041 and P = 0.022 respectively, log-rank test). 
HCC = hepatocellular carcinoma.
Subgroup analysis
In a subgroup analysis, 62 patients before the guideline implementation with normal AST and 
ALT with high HBV DNA not started on AVT and 93 patients after the guideline implementation 
with normal ALT with high HBV DNA started on AVT were selected. In these two subgroups, 
there were two and seven cases of HCC, respectively. The cumulative incidence rates of HCC 
were statistically similar between the two subgroups (P = 0.271 by log-rank test).
NHIS data analysis
Among 48,225 patients with compensated CHB-related cirrhosis, 24,280 were treated before 
the guideline implementation and 23,975 were treated after the guideline implementation 
(Supplementary Table 1). Patients treated after the guideline implementation had a 
significantly higher age (median 48.3 vs. 47.3), lower percentage of male gender (62.8% vs. 
63.7%), and lower proportion of TDF use (70.4% vs. 75.2%) than those treated before the 
guideline implementation (all P < 0.05).
In multivariate analysis, higher age, male gender, and diabetes mellitus were independently 
associated with a higher risk of HCC development (all P < 0.05), whereas AVT initiation 
before the guideline implementation showed only a trend of association with increased risk 
of HCC development (HR, 1.04; 95% CI, 0.96–1.12; P = 0.338) (Supplementary Table 2).
PSM analysis
When age, gender, HBV DNA, and HBeAg positivity were adjusted in the PSM analysis, a total 
of 344 (172 with pre-guideline implementation vs. 172 with post-guideline implementation) 
patients were selected for comparison (Supplementary Table 3). In multivariate analysis, 
AVT initiation before the guideline implementation was independently associated with the 
increased risk of HCC development, when compared to AVT initiation after the guideline 
implementation (HR, 2.016; 95% CI, 1.034–3.933; P = 0.040), together with older age 
(Supplementary Table 4).
Similarly, AVT initiation before the guideline implementation was independently associated 
with the increased risk of mortality or liver transplant, when compared to AVT initiation after 
the guideline implementation (HR, 3.411; 95% CI, 1.262–9.388; P = 0.016), together with 
lower platelet count (Supplementary Table 5).
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Table 3. Cox regression analysis to identify independent risk factors for mortality or liver transplant
Variables Univariate Multivariate
P value HR 95% CI P value
Age, yr 0.185
Age > 50 yr 0.592
Male (vs. female) 0.014 3.590 1.359–9.485 0.010
Body mass index, kg/m2 0.756
Diabetes 0.060
Alanine aminotransferase, IU/L 0.991
Alanine aminotransferase > 40 IU/L 0.589
Aspartate aminotransferase, IU/L 0.171
Platelet count, 109/L 0.025 0.989 0.979–0.999 0.029
Alpha-fetoprotein, ng/mL 0.156
HBeAg positivity 0.353
HBV DNA, log IU/mL 0.356
Entecavir (vs. tenofovir) 0.418
Pre-guideline implementation (vs. post-guideline implementation) 0.027 2.309 1.036–5.145 0.041
HR = hazard ratio, CI = confidence interval, HBeAg = hepatitis B e antigen, HBV = Hepatitis B virus.
DISCUSSION
In our study, patients with CHB with AVT initiation before the KASL guideline implementation 
showed unfavorable outcomes, compared to those treated after the KASL guideline 
implementation. Specifically, AVT initiation before the guideline implementation was 
independently associated with an increased risk of HCC development (HR = 1.833), together 
with older age (HR = 1.041) and male gender (HR = 2.719). In addition, AVT initiation before 
the guideline implementation independently predicted a higher risk of mortality or liver 
transplantation (HR = 2.400), together with male gender (HR = 3.056). However, NHIS data 
analysis showed that patients with AVT initiation before guideline implementation tended to 
show higher rates of HCC development, mortality, and liver transplantation.
Our study has several clinical implications. It is the first to confirm that the long-term 
clinical outcomes of CHB-related cirrhotic patients significantly improved after the recent 
modification of the KASL guideline on AVT treatment and its reimbursement. Despite the 
retrospective design of our study, our results indicate that appropriate changes in national 
policy management guidelines may be critical for improvement of treatment outcomes in 
high risk patients. Although our study focused on the clinical significance of the time point 
“before and after the revised medical insurance reimbursement for AVT,” we believe that the 
time point addresses both cohort effects and ALT levels at the beginning of AVT. Since the 
revised AVT guideline was devised to decrease the barrier to initiation of AVT by removing AST 
and ALT levels as treatment indications, our data support both the effectiveness of lowering 
AST and ALT requirements for AVT and the effectiveness of the national policy by showing 
significant decreases in the risk of HCC and liver transplant or mortality. Several studies have 
already shown that elevated ALT is not an accurate predictor of disease progression in CHB-
related cirrhotic patients, which may explain the clinical significance for lowering AST and ALT 
requirements for AVT. Lai et al.19 found that 37% of patients with persistently normal ALT had 
significant fibrosis and inflammation. Similarly, Kumar et al. found that 40.2% of patients with 
persistently normal ALT levels had a histological fibrosis score ≥ 2.20 These findings support 
the fact that cirrhotic patients with CHB disease progression may present with normal ALT 
and that such patients could be overlooked when using older guidelines. Our results suggest 
that lowering the AVT initiation criteria to include patients with normal ALT and AST levels 
through public policy could delay disease progression toward clinical endpoints, such as 
decompensated cirrhosis or HCC, with early intervention.
Second, our results are supported by the relatively large sample size from two tertiary, academic 
institutes with sufficient laboratory and imaging findings (n > 400). In addition, we validated 
our results using a large sample derived from the NHIS database; however, the NHIS data only 
showed a trend for an increased risk of poor outcomes for AVT initiation before the guideline 
implementation. Despite only showing a trend, we believe that such data may be helpful in 
recruiting subsequent studies with large hospital samples. Because of the selection of high-
risk patients, such as patients with cirrhosis, the proportion of patients who developed HCC 
was relatively high (> 11%), despite of the relatively short follow-up period. In contrast, in our 
cohort, we were able to identify well-known risk factors for HCC development, such as age and 
gender as independent predictors, suggesting a lower risk of statistical errors.
Third, we also performed PSM analysis to adjust the clinical and laboratory characteristics 
between two cohorts. Similar to the main results from hospital cohorts, AVT initiation 
before the guideline implementation was independently associated with an increased risk of 
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HCC and mortality or liver transplant after PSM, when compared to AVT initiation after the 
guideline implementation.
We are also aware of several limitations in our study that remain unresolved. First, our 
study involved a relatively short follow-up period (median 36.3 months). Due to the NHIS 
reimbursement date for the current AVT guideline being September 1, 2015, with an 
enrollment period of 14 months, follow-up of the post-guideline implementation guideline 
cohort was limited to 45 months, which may be inadequate to ensure development of an 
appropriate number HCC events for analysis. However, the enrollment of high-risk patients 
with cirrhosis resulted in sufficient event development, which contributed to overcoming 
the potential statistical limitation due to a short follow-up period. Second, although 
analyzed together with mortality to achieve stronger statistical power, the incidence of liver 
transplantation was rare in our data, which may have led to biased analysis of such events. 
We believe longer term studies with a sufficient number of various liver-related events may 
be required. Third, we could not effectively compare patients treated before and after the 
guideline implementation with high HBV DNA and normal AST and ALT levels due to the 
relatively small sample sizes in each subgroup (n = 62 vs. 93, respectively) and the small 
number of HCC cases in each group (n = 2 vs. 7, respectively). Due to these reasons, the 
cumulative incidence rate of HCC was statistically similar between the two cohorts (P = 
0.271), although our results might be susceptible to false negative errors. Fourth, study 
participants were recruited from tertiary, academic institutes. We believe this might be the 
reason for higher proportions of patients initiated on ETV after the guideline implementation 
in 2015, as physicians might be more hesitant to initiate tenofovir in older patients at risk of 
chronic kidney disease or bone issues in tertiary referral institutes.21,22 However, because 
recent studies have shown that the type of AVT agent does not influence the risk of HCC 
incidence, the main findings of our study might not have been influenced by the type of 
antiviral agent.8,23 Additionally, although our study results may not be fully applicable in 
the primary care setting, the care and follow up of patients with cirrhosis is usually done at 
tertiary institutes, thus enhancing the clinical significance of our study. Finally, although the 
NHIS patient data only revealed a trend of an increased risk for poor patient outcomes pre-
guideline implementation, the lack of detailed clinical and laboratory information, such as 
fibrotic burden and liver function, may be pose potential bias.
In conclusion, the prognosis of patients with CHB-related cirrhosis who underwent AVT 
improved after implementation of the revised KASL guideline.
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